| Literature DB >> 18578516 |
Jason Xiang1, Zhao-Kui Wan, Huan-Qiu Li, Manus Ipek, Eva Binnun, Jill Nunez, Lihren Chen, John C McKew, Tarek S Mansour, Xin Xu, Vipin Suri, May Tam, Yuzhe Xing, Xiangping Li, Seung Hahm, James Tobin, Eddine Saiah.
Abstract
11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is the enzyme that converts cortisone to cortisol. Evidence suggests that selective inhibition of 11beta-HSD1 could treat diabetes and metabolic syndrome. Presented herein are the synthesis, structure-activity relationship, and in vivo evaluation of piperazine sulfonamides as 11beta-HSD1 inhibitors. Through modification of our initial lead 5a, we have identified potent and selective 11beta-HSD1 inhibitors such as 13q and 13u with good pharmacokinetic properties.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18578516 DOI: 10.1021/jm8004948
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446